The ready-to-use formulation of bortezomib is now an FDA-approved option for patients with multiple myeloma and mantle cell lymphoma.
A new, ready-to-use, subcutaneous version of bortezomib has been approved by the FDA.1
Reconstitution before use is not required, in contrast with the branded bortezomib product Velcade, which is a lyophilized powder. The ready-to-use formulation offers greater flexibility and speed of administration.
"We are building a distinct branded oncology injectable portfolio. The approval of Boruzu is our fourth 505(b)(2) injectable approval this year. These ready-to-use injectable presentations are important innovations for oncology providers as they reduce the pharmacy preparation steps for clinicians. We look forward to bringing more branded oncology products to the market for providers while expanding access for patients," said Sean McGowan, vice president of biosimilars and branded oncology at Amneal Pharamaceuticals, in a press release.
This bortezomib injection is indicated for use in adult patients with multiple myeloma or mantle cell lymphoma.2 A phase 3 noninferiority study (NCT00722566) evaluated the efficacy and safety of subcutaneous vs intravenous bortezomib in patients with multiple myeloma. A total of 222 patients with bortezomib-naive relapsed multiple myeloma were included and randomly assigned 2:1 to receive 1.3 mg/m2 of subcutaneous (n = 148) or intravenous (n = 74) bortezomib. After 4 cycles, the overall response rate (ORR) in the subcutaneous bortezomib arm was 43% vs 42% in the intravenous arm. In the subcutaneous arm, 7% of patients achieved a complete response (CR) and 35% achieved a partial response (PR) compared with 8% and 34% in the intravenous arm, respectively.
Regarding safety, the most commonly reported adverse effects from the subcutaneous bortezomib administration were asthenic conditions, diarrhea, nausea, constipation, peripheral neuropathy, vomiting, pyrexia, thrombocytopenia, psychiatric disorders, anorexia/decreased appetite, neutropenia, neuralgia, leukopenia, and anemia.
Comparatively, the most commonly reported adverse events with intravenously administered bortezomib include nausea, diarrhea, thrombocytopenia, peripheral neuropathy, fatigue, neuralgia, anemia, leukopenia, constipation, vomiting, lymphopenia, rash, pyrexia, and anorexia.3
Lenalidomide Break Possible? Study Shows Hope for MRD-Negative Myeloma
October 7th 2024A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes.
Read More